References
- Shelling AN. Premature ovarian failure. Reproduction. 2010 Nov;140(5):633–641.
- Kokcu A. Premature ovarian failure from current perspective. Gynecological Endocrinol. 2010 Aug;26(8):555–562.
- Ebrahimi M, Akbari Asbagh F. Pathogenesis and causes of premature ovarian failure: an update. Int J Fertil Steril. 2011 Jul;5(2):54–65.
- Jankowska K. Premature ovarian failure. Przeglad Menopauzalny. 2017 Jun;16(2):51–56.
- Schmidt KT, Rosendahl M, Ernst E, et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil Steril. 2011 Feb;95(2):695–701.
- Arora P, Polson DW. Diagnosis and management of premature ovarian failure. Obstetrician Gynaecologist. 2011;13(2):67–72.
- Maclaran K, Horner E, Panay N. Premature ovarian failure: long-term sequelae. Menopause Int. 2010 Mar;16(1):38–41.
- Sassarini J, Lumsden MA, Critchley HO. Sex hormone replacement in ovarian failure - new treatment concepts. Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):105–114.
- Kovanci E, Schutt AK. Premature ovarian failure: clinical presentation and treatment. Obstet Gynecol Clin North Am. 2015 Mar;42(1):153–161.
- Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol. 2010 Nov;45(5):257–279.
- Chen Z, Kang X, Wang L, et al. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure. J Biol Chem. 2015 Mar 6;290(10):6387–6396.
- Yamchi NN, Rahbarghazi R, Bedate AM, et al. Menstrual blood CD146+ mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure. Cell Biochem Funct. 2021 Dec;39(8):998–1008.
- Sheshpari S, Shahnazi M, Ahmadian S, et al. Intra-ovarian injection of bone marrow-derived c-Kit+ cells for ovarian rejuvenation in menopausal rats. BioImpacts. 2021. DOI:10.34172/bi.2021.23499.
- Gupta S, Lodha P, Karthick MS, et al. Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: review of literature and a case report of world’s first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year. J Hum Reprod Sci. 2018 Apr-Jun;11(2):125–130.
- Na J, Kim GJ. Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review. J Ovarian Res. 2020 Jun;13(1):74.
- Chen X, Yan GY. Novel human lncRNA-disease association inference based on lncRNA expression profiles. Bioinformatics. 2013 Oct 15;29(20):2617–2624.
- Yao H, Chen R, Yang Y, et al. LncRNA BBOX1-AS1 aggravates the development of ovarian cancer by sequestering miR-361-3p to augment PODXL expression. Reprod Sci. 2021 Mar;28(3):736–744.
- Li Q, Du X, Liu L, et al. Upregulation of miR-146b promotes porcine ovarian granulosa cell apoptosis by attenuating CYP19A1. Domest Anim Endocrinol. 2021;74:106509.
- Liu T, Lin J, Chen C, et al. MicroRNA-146b-5p overexpression attenuates premature ovarian failure in mice by inhibiting the Dab2ip/Ask1/p38-Mapk pathway and γH2A.X phosphorylation. Cell Prolif. 2021 Jan;54(1):e12954.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25(4):402–408.
- Grentzmann G, Ingram JA, Kelly PJ, et al. A dual-luciferase reporter system for studying recoding signals. RNA. 1998;4(4):479–486.
- Liu Z, Li F, Xue J, et al. Esculentoside A rescues granulosa cell apoptosis and folliculogenesis in mice with premature ovarian failure. Aging (Albany NY). 2020 Aug 5;12(17):16951–16962.
- Chen J, Zhou Q, Zhang Y, et al. Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure. Bioengineered. 2021;12(1):8778–8792.
- Cao Y, Chen Y, Wang P, et al. Network pharmacology and experimental validation to explore the molecular mechanisms of Bushen Huoxue for the treatment of premature ovarian insufficiency. Bioengineered. 2021;12(2):10345–10362.